If you receive a denial letter from your insurer, don’t appeal the decision before seeking legal advice, says a leading ...
Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA ...
Research Grants and 7 Development Awards for Fellowship Trainees Will Fund Critical Research Across Multiple Neuromuscular ...
Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...
VectorY Therapeutics appoints Jim Scibetta as CEO to lead development of VTx-002, a vectorized antibody therapy targeting TDP ...
Ulefnersen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Amyotrophic Lateral Sclerosis.
Texas Lt. Gov. Dan Patrick has vowed to try and ban all THC and marijuana compounds, but a local shop owner says it could be ...
StockNews.com cut shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) from a buy rating to a hold rating in a report published on Friday morning. A number of other equities analysts also ...
Stifel Financial Corp boosted its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 15.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback